- Home
- PMVP vs RLMD Comparison
PMVP vs RLMD Comparison
Compare PMVP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- RLMD
- Stock Information
- Founded
- PMVP 2013
- RLMD 2004
- Country
- PMVP United States
- RLMD United States
- Employees
- PMVP N/A
- RLMD N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- RLMD Health Care
- Exchange
- PMVP Nasdaq
- RLMD Nasdaq
- Market Cap
- PMVP 76.8M
- RLMD 66.7M
- IPO Year
- PMVP 2020
- RLMD N/A
- Fundamental
- Price
- PMVP $1.42
- RLMD $2.13
- Analyst Decision
- PMVP Strong Buy
- RLMD Hold
- Analyst Count
- PMVP 1
- RLMD 2
- Target Price
- PMVP $5.00
- RLMD $1.00
- AVG Volume (30 Days)
- PMVP 949.9K
- RLMD 517.2K
- Earning Date
- PMVP 11-06-2025
- RLMD 11-06-2025
- Dividend Yield
- PMVP N/A
- RLMD N/A
- EPS Growth
- PMVP N/A
- RLMD N/A
- EPS
- PMVP N/A
- RLMD N/A
- Revenue
- PMVP N/A
- RLMD N/A
- Revenue This Year
- PMVP N/A
- RLMD N/A
- Revenue Next Year
- PMVP N/A
- RLMD N/A
- P/E Ratio
- PMVP N/A
- RLMD N/A
- Revenue Growth
- PMVP N/A
- RLMD N/A
- 52 Week Low
- PMVP $0.81
- RLMD $0.24
- 52 Week High
- PMVP $1.84
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- PMVP 50.54
- RLMD 59.09
- Support Level
- PMVP $1.36
- RLMD $1.89
- Resistance Level
- PMVP $1.49
- RLMD $2.84
- Average True Range (ATR)
- PMVP 0.08
- RLMD 0.28
- MACD
- PMVP 0.01
- RLMD -0.01
- Stochastic Oscillator
- PMVP 57.41
- RLMD 36.50
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.